Skip to Content
Merck
CN
  • Generation of T cells from Human and Nonhuman Primate Pluripotent Stem Cells.

Generation of T cells from Human and Nonhuman Primate Pluripotent Stem Cells.

Bio-protocol (2021-03-05)
Akhilesh Kumar, Saritha S D'Souza, Gene Uenishi, Mi Ae Park, Jeong Hee Lee, Igor I Slukvin
ABSTRACT

Pluripotent stem cells (PSCs) have the potential to provide homogeneous cell populations of T cells that can be grown at a clinical scale and genetically engineered to meet specific clinical needs. OP9-DLL4, a stromal line ectopically expressing the Notch ligand Delta-like 4 (DLL4) is used to support differentiation of PSCs to T-lymphocytes. This article outlines several protocols related to generation of T cells from human and non-human primate (NHP) PSCs, including initial hematopoietic differentiation of PSC on OP9 feeders or defined conditions, followed by coculture of the OP9-DLL4 cells with the PSC-derived hematopoietic progenitors (HPs), leading to efficient differentiation to T lymphocytes. In addition, we describe a protocol for robust T cell generation from hPSCs conditionally expressing ETS1. The presented protocols provide a platform for T cell production for disease modeling and evaluating their use for immunotherapy in large animal models.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
holo-Transferrin human, powder, BioReagent, suitable for cell culture, ≥97%
Sigma-Aldrich
HEPES, BioPerformance Certified, ≥99.5% (titration), suitable for cell culture
Sigma-Aldrich
D-(+)-Glucose, ≥99.5% (GC)
Sigma-Aldrich
Hexadimethrine bromide, ≥94% (titration)
Sigma-Aldrich
Sodium selenite, BioReagent, suitable for cell culture, ≥98%
Sigma-Aldrich
Human Tenascin-C Purified Protein
Sigma-Aldrich
Collagen from human placenta, Bornstein and Traub Type IV, powder, BioReagent, suitable for cell culture